Project Grant R01CA309386
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $556K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $140,400 on July 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop multimodal, interpretable artificial intelligence models that integrate digital pathology images and tumor genomic data to improve precision cancer diagnosis and treatment selection. The award funds a two-phase K99/R00 career development grant. During the K99 phase, the recipient will study multimodal self-supervised...
- The National Cancer Institute awarded Duke University $109,767 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and validate pathway-centric artificial intelligence frameworks for analyzing colorectal cancer heterogeneity using single-cell and spatial transcriptomic data. The project, spanning July 1, 2026, through June 30, 2038, will be performed in Durham, North Carolina. During the K99 mentored phase, the recipient will develop SPACT, an interpretable AI...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Baylor University $168,839 on July 17, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test geospatial artificial intelligence methods for sub-county cancer surveillance. The project applies neural cellular automata and graph neural networks to create geographic boundaries that improve cancer surveillance using individual-level cancer incidence data from the Texas...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $394,695 to The Ohio State University on June 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate computational approaches for detecting and characterizing infiltrating immune cells in breast cancer. The recipient will develop computational methods to enumerate and phenotype tumor-infiltrating lymphocytes (TILs) and...
- The National Cancer Institute (part of the National Institutes of Health under the Department of Health and Human Services) awarded New York University School of Medicine $700,171 on July 16, 2026, to advance deep learning models for clinically significant prostate cancer detection on magnetic resonance imaging. The funded research addresses three specific aims: training a robust deep learning model on diverse imaging datasets to ensure consistent performance across multiple scanners, protocols,...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded the University of Washington $686,271 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support proteomics-driven analysis and robotics-enabled drug testing of microdissected tumors and their microenvironment. The funded work develops high-throughput approaches to rapidly dissect thousands of regularly-sized microdissected tumor tissues (MDTs) from single biopsies. Tumor tissue is mechanically cut into approximately...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The Leland Stanford Junior University $606,756 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development and validation of foundation model-augmented artificial intelligence tools to enable accurate and efficient image guidance in upright proton therapy for lung cancer treatment. The research will create a vision-language framework for...
- The National Cancer Institute awarded The University of Chicago $249,000 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop explainable artificial intelligence models for predicting early-stage melanoma recurrence through integrative analysis of multiplexed tissue imaging, spatial transcriptomics, and clinical histopathology data. The research addresses the gap between current inadequate prognostic tools and the clinical need to identify...
- The National Cancer Institute awarded Georgetown University $412,167 on July 8, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop artificial intelligence tools for extracting and predicting immune-related adverse events in cancer immunotherapy patients. Georgetown will build a natural language processing pipeline and hybrid machine learning models to automate the extraction of immune-related adverse event evidence, type, and grade from de-identified...